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Abstract 
Prodrug is a chemical devise in which the drug is covalently linked to a chemical moiety; this 
linked moiety will temporarily affect the physicochemical properties of the drug for increasing 
their usefulness or decreasing their toxicity. The prodrug should be converted to its active form 
by metabolic or/and chemical processes, conversion process involves metabolism by enzymes 
distributed throughout the body. These enzymes might either decrease the drug’s bioavailability, 
or a genetic polymorphisms might lead to variability in prodrug activation and thus affect the 
efficacy and safety of designed prodrug. In the past few decades computational chemistry 
methods have been utilized in calculating physicochemical and molecular properties of 
compounds. This tool can be used to design prodrugs that chemically (intramolecular processes) 
interconvert to their parent drugs without any involvement of enzyme catalysis. The release of 
the active drug is solely dependent on the rate limiting step of the intramolecular process. Based 
on DFT calculations four different tranexamic acid prodrugs and three different bitter less 
paracetamol prodrugs were designed, synthesized and characterized using FT-IR, 1H-NMR LC-
MS and their in vitro intra-conversion to their parent drugs revealed that the t1/2 was largely 
affected by the pH of the medium. For tranexamic acid ProD 1 the experimental t1/2 values in 1N 
HCl, buffer pH 2 and buffer pH 5 were 54 minutes, 23.9 hours and 270 hours, respectively. 
Tranexamic acid ProD 2 was readily converted in 1 N HCl and pH 2 while it was entirely stable 
at pH 5 and pH 7.4. On the other hand, tranexamic acid ProD 3 and Prod 4 were stable in all 
media studied. The experimental t1/2 values for paracetamol ProD 2 in pH 3 and pH 7.4 were 3 
hours and 18 minutes respectively and for paracetamol ProD 3 it was 27 hours in pH 3 and 12 
hours in pH 7.4. In vitro binding for paracetamol ProD 2 to bitter taste receptors revealed that 
this prodrug lacks any binding affinity and it was found not to have any bitter sensation. This 
suggests, that paracetamol ProD 2 can replace its parent drug, paracetamol, for the use as 
bitterless antipyretic drug for geriatrics and pediatrics.  
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Chapter one 
1. Introduction 
1.1. Background  
The prodrug term was firstly introduced by Albert [1]. Prodrug is a chemical devise in 
which the drug is covalently linked to a chemical moiety; this linked moiety will 
temporarily affect the physicochemical properties of the drug in order to increase its 
usefulness or decrease its toxicity. The prodrug should be converted to its active form by 
metabolic or/and chemical processes. It was reported that about 10% of marketed 
medications are prodrugs, 20% of medicines that were approved between 2000 and 2008 
were prodrugs. Therefore, nowadays the interest in prodrug approach becomes more and 
more popular in pharmaceutical industries [2, 3]. 
Ideally the prodrug should be converted to the active parent drug at the site of action; 
according to the site of action prodrugs can be classified into type I and type II and 
subtypes IA, IB, IIA, IIB or IIC. Type I are prodrugs that are converted to their parent 
drugs intracellularly. For subtype IA, the conversion occurs at cellular therapeutic target 
while in subtype IB the conversion of the prodrug occurs in metabolic tissues such as 
liver, but if the conversion of the prodrug occurs extracellularly, it will be classified as 
type II prodrug. When the conversion process occurs in gastrointestinal fluid it will be 
classified as subtype IIA, if the process occurs in  systemic circulation or in systemic 
extracellular fluid the prodrug will be classified as subtype IIB, and if the conversion 
occurs near the target cell it will be classified as subtype IIC [4]. 
An ideal prodrug should  have a rapid transformation to active drug when it reaches the 
target of interest chemically or enzymatically, and the linked moiety should be a  non-
toxic moiety [5]. 
Prodrug approach became very popular in drug development process to overcome 
problems related to pharmacokinetics (ADME) and toxicity which are the main factors of 
high attrition in drug development process so the process will be cost effective and less 
time consuming [6]. 
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Applications of prodrug approach: 
A. Improving solubility and bioavailability 
Poor solubility of drug will be a challenge when dissolution of the drug from a dosage 
form is the rate limiting step. Many techniques are used to overcome solubility problem 
as salt formation and solubility enhancer excipients, prodrug can also be used as an 
alternative technique to increase aqueous solubility of parent drug by attaching polar 
groups such as phosphate, amino acids and sugar moieties [7-9]. 
If the prodrug contains a phosphate group, the parent drug will be readily released  by 
endogenous phosphatase as alkaline phosphatase, while if it contains amino acid esters 
or amides the prodrug will be cleaved by esterase or amidases available in plasma or 
tissues, and if it contains sugar moieties such as glucose, β-glucosidase will be utilized 
to convert the prodrug to its corresponding parent drug [2]. 
 
B. Increasing permeability and absorption 
For a drug to be absorbed, it should pass through many membranes, this requires a 
lipophilic group to be in the drug structure so if the drug contains polar groups it will 
have a limited permeability and then low absorption profile. The prodrug strategy can be 
used to enhance permeability by masking the polar group as hydroxyl, thiol, carboxyl, 
phosphate or amino acid with more lipophilic alkyl or aryl esters and these prodrugs can 
be readily converted to the parent drugs via hydrolysis catalyzed by esterase enzyme 
[10]. 
 
C. Changing distribution profile 
This approach can be accomplished using a prodrug to deliver a parent drug to a specific 
target utilizing site- selective endogenous enzymes to convert the prodrug to its active 
parent drug. In addition, this approach may also be used to decrease drug toxicity [2]. 
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D. Improving taste 
If a drug has unpleasant taste, it will decrease the patient compliance and hence 
decreasing the efficacy of the drug. Prodrugs can be used to improve the taste of the 
parent drugs either by decreasing their solubility in saliva or by masking the functional 
group that is responsible for the binding to the taste receptors located on the tongue and 
thus to reducing the unpleasant taste [11]. 
Successfully designed prodrug should be activated to its parent drug; activation process 
involves metabolism by enzymes distributed throughout the body, hydrolytic enzymes as 
esterases and amidases and non-hydrolytic enzymes such as cytochrome P450 are the 
most important enzymes involved in the bioactivation process of prodrugs. 
Enzymes accelerate the rate of chemical reactions that the substrate (drug) might undergo 
in physiological environment. The reaction rate in the majority of enzymatic reactions is 
1010 to 1018 fold the non-enzymatic reaction [12]. 
When the prodrug is designed to be activated by  natural enzymes such as esterases and 
amidases, the prodrug might be tackled by a premature hydrolysis during the absorption 
phase in enterocytes of gastrointestinal tract, this might produce more polar and less 
permeable prodrug which results in  a decreased bioavailability (50%),  while if the 
prodrug is activated by cytochrom P450 enzymes which are responsible for 75% of the 
enzymatic metabolism of prodrugs, a genetic polymorphisms might persist and then lead 
to variability in prodrug activation and thus affect the efficacy and safety of designed 
prodrugs [12].  Thus, it might be difficult to predict the bioconversion rate of the 
enzymatic hydrolysis of the prodrug and hence a difficulty in predicting their 
pharmacological or toxicological effects.  
In the past few decades, computational chemistry has been utilized in calculating 
physicochemical and molecular properties of compounds. Using molecular orbital (MO) 
and molecular mechanics (MM) methods prediction of chemical reactions could be done.  
This tool can be used to design prodrugs that can chemically interconvert to their parent 
drugs without any involvement of enzyme catalysis. The release of the active drug will be 
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solely dependent on the rate limiting step of the intramolecular process (prodrug chemical 
features) [13].  
1.2. Tranexamic acid 
(trans-4 (aminomethyl) cyclohexanecarboxylic acid) (Figure 1.1) is a synthetic lysine 
derivative, it is used as antifibrinolytic to treat excessive blood loss during surgery and 
in other medical conditions as hemorrhage in hemophilia patients and the bleeding in 
tooth extraction procedure, it is a competitive inhibitor of plasminogen that prevents the 
activation of plasminogen to plasmin; plasmin is an enzyme used to degrade fibrin clot. 
It is an important agent in decreasing mortality rate due to bleeding in trauma patients; 
this can be seen from CRASH-2 study which concludes that  all caused mortality, 
relative risk and relative death due to bleeding were reduced with a tranexamic acid 
group more than a placebo group [14]. It can be used safely in women who undergo 
lower segment cesarean section; in this operation it was found that tranexamic acid 
reduced the blood loss during and after surgery [15] , and it is pharmacologically active 
in reducing blood using in intra-operative heart, hip and knee replacement and liver 
transplant surgeries [16]. 
Tranexamic acid is considered as an effective medication and safe non hormonal therapy 
for the management of heavy blood loss during menstrual cycle and so improve 
women`s life quality during menses [17]. In a randomized controlled trial it was 
conclude that oral tranexamic acid is effective in decreasing blood loss during menstrual 
cycle by 40%.  The total oral dose recommended in women with heavy menstrual 
bleeding was two 650 mg tablets three times daily for 5 days [18]. 
After the withdrawing of aprotinin from worldwide market at 5 November 2009, 
tranexamic acid is the only marketed antifibrinolytic agent available in the market [19]. 
 It was found that tranexamic acid also is effective in inhibiting the activity of urokinase 
in urine [20]; so it is safe and effective to treat severe hematuria in patient with chronic 
renal impairment that poorly respond to conventional therapy [21].  
It was found that tranexamic acid inhibit the ultraviolet radiation induced pigmentation 
activity hence it can be used as bleaching agents; oral tranexamic acid is effective and 
safe in treating malesma which is a hypermelanosis disease that occurs in Asian women 
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and oral tranexamic acid is a non-invasive and non-irritating treatment for this disease 
[22]. 
 
 
 
 
1.3. Paracetamol 
Paracetamol (N-(4-hydroxyphenyl)ethanamide, Figure 1.2) is an over the counter 
analgesic and anti-pyretic drug. It is used to relief minor aches. it is used as pain killer by 
decreasing the synthesis of prostaglandin due to inhibiting cyclooxygenases  [23]. 
Paracetamol is favored over aspirin as pain killer in patients who have excessive gastric 
secretion or prolonged bleeding [24]. It was approved to be used as fever reducer in all 
ages. Bitter unpleasant taste is one of paracetamol undesired properties. 
 
Figure 1.2. Chemical structure of paracetamol 
 
 
Figure 1.1. Chemical structure of tranexamic acid. 
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1.3.1 Taste background 
Taste is an important issue for orally administered drugs; one of the most serious 
problems for drug formulation is the undesirable drug’s taste. Drugs bitterness might 
reduce patient compliance thus decreasing therapeutic effect especially in children 
patients. Therefore, masking the bitter taste of a drug is an important issue in the 
pharmaceuticals industry. 
There are five basic tastes; sweet, sour, salt, bitter and umami. When a molecule 
dissolves in saliva it binds to a taste receptor that is found in taste buds which are 
distributed throughout the tongue. Sweet receptors are located on the tip of the tongue, 
sour receptors are located on the bilateral sides of tongue, salty taste receptors are located 
in the bilateral sides and the tip of the tongue, bitter taste receptors are located on the 
posterior part of the tongue and umami taste receptors are located all over the tongue. 
When  a molecule binds to a receptor, a signal will be transmitted to the brain via facial, 
glossopharyngeal and vagus cranial nerves [25]. 
 Human bitter taste receptors are mediated by 25 G-coupled protein receptor hTAS2Rs 
[26].  Binding of a bitter taste molecule to a bitter taste receptor causes an activation of a 
G-coupled protein receptor which leads to split α, β, γ sub units, and then a second 
messenger is activated leading to an increase in Ca+2 concentration inside the cell, thus 
causing a depolarization of a neuron to produce a signal which is transferred and 
interpreted in the brain as bitter taste [27]. 
1.4.  Research problem 
1.4.1 Tranexamic acid 
Due to the amino acid nature of tranexamic acid, it can be concluded that tranexamic acid 
has a low bioavailability because at physiological pH it will be in an ionized form; this 
ionization will decrease the ability of tranexamic acid to be transferred to the systemic 
blood circulation and hence only 34% of tranexamic acid will be available in the systemic 
circulation [28]. 
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Thus, using the prodrug approach to increase tranexamic acid bioavailability can be 
utilized. This can be achieved by making a covalent linkage between tranexamic acid and 
a non-toxic promoiety that increases the lipophilicity of tranexamic acid.  
The proposed prodrug was designed using computational methods such that the prodrug 
will be intraconverted to tranexamic acid and non-toxic moiety in a rate which is only 
dependent on the structural features of the inactive linker. 
1.4.2. Paracetamol 
Paracetamol has a strong bitter taste (Figure 1.3). The bitter unpleasant taste of a drug 
might reduce patient compliance.  Paracetamol was found in the urine of patients who 
had taken phenacetin and later on, it was demonstrated that paracetamol was a urinary 
metabolite of acetanilide (Figure 1.3). Phenacetin (Figure 1.3), on the other hand, lacks or 
has a very slight bitter taste. Examination of the structures of paracetamol and phenacetin 
reveals that the only difference in the structural features is the nature of the group in the 
para position of the benzene ring. While in the case of paracetamol the group is hydroxy, 
in phenacetin it is ethoxy. Acetanilide has a chemical structure similar to that of 
paracetamol and phenacetin but lacks the group in the para position of the benzene ring, 
making it lack the bitter taste characteristic of paracetamol. These combined facts suggest 
that the presence of a hydroxy group on the para position is the major contributor for the 
bitter taste of paracetamol. Therefore, it is expected that blocking the hydroxyl group in 
paracetamol with a suitable linker could inhibit the interaction of paracetamol with its 
bitter taste receptors and mask its bitter taste [29]. 
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Figure 1.  3 . Chemical structures of (a) paracetamol, (b) phenacetin and (c) acetanilide. 
1.5. Thesis objectives 
General Objective: 
The main goal of this research was to synthesize and to study the kinetics for the 
following novel prodrugs: tranexamic acid maleate, tranexamic acid dimethyl maleate, 
tranexamic acid succinate, tranexamic acid dimethyl succinate, paracetamol maleate, 
paracetamol succinate and paracetamol glutarate. 
 
Specific objectives: 
1. To synthesize tranexamic acid prodrugs with the following characteristics: 
 To be readily dissolved in physiological media. 
 To increase the bioavailability profile. 
 To have moderate hydrophilic lipophilic balance (HLB) value. 
 To be converted to tranexamic acid in a programmable manner. 
 To give a safe non-toxic linker moiety after conversion process. 
2. To synthesize paracetamol prodrugs with following characteristics: 
 Lack bitter taste. 
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 To give safe non-toxic linker moiety after conversion process. 
3. To perform in vitro Kinetic studies of tranexamic acid prodrugs and paracetamol 
prodrugs at different pHs mimicking the physiological media. 
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Chapter Two 
2. Literature Review 
2.1.  Introduction 
Nowadays, quantum mechanics (QM) such as ab initio, semi-empirical and density 
functional theory (DFT) and molecular mechanics (MM) are recommended to provide 
structure energy calculations  for prediction of drugs and prodrugs alike [30-34]. 
The ab initio molecular orbital methods are based on rigorous use of Schrodinger 
equation with number of approximations. Ab initio methods can be applied only on small 
system containing not more than thirty atoms. Semi-empirical method is applied on 
molecules with more than 50 atoms and gives information for practical application [35, 
36]. DFT method is a semi-empirical method used for medium sized systems and it’s not 
restricted to the second row of the periodic table [37]. 
The mechanisms of some intramolecular processes that were advocated to understand 
enzyme catalysis (enzyme models) were investigated to design novel prodrug linkers [29, 
38-56]. Among the studied intramolecular processes:  
o Acid-catalyzed lactonization of hydroxy-acids as researched by Cohen [30, 57, 58] 
and Menger [59-65]. 
o SN2-based ring closing reactions as studied by Brown, Bruice, and Mandolini [31, 32, 
66]. 
o Proton transfer between two oxygens in Kirby’s acetals [67-71], and proton transfer 
between nitrogen and oxygen in Kirby’s enzyme models [67-71], proton transfer from 
oxygen to carbon in some of Kirby’s enol ethers [67-71]. 
The computational calculations using DFT and ab initio methods carried by Karaman’s 
group revealed the followings: (i) rates acceleration in intramolecular processes is a result 
of both entropy and enthalpy effects. In intramolecular ring-closing reactions where 
enthalpic effects were predominant, steric effects were the determining factor for the 
acceleration, whereas proximity orientation was the determining factor in proton-transfer 
reactions. (ii) The distance between the two reacting centers is the main factor in 
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determining whether the reaction type is intermolecular or intramolecular.  When the 
distance exceeded 3 Å, an intermolecular engagement was preferred because of the 
engagement with a water molecule (solvent). When the distance between the electrophile 
and nucleophile was < 3 Å, an intramolecular reaction was dominant [38-55, 72]. 
Based on previous studies on enzyme models a design of a prodrug with modified 
pharmacokinetics properties that can releases the parent drug in a slow or fast manner 
could be accomplished [6]. 
2.2.  Design of Tranexamic acid prodrug using Kirby`s enzyme model (Proton 
transfer in N-alkylmaleamic acids) 
Acid-catalyzed hydrolysis of N-alkylmaleamic acids 1-9 (Figure 2.1) was kinetically 
studied by Kirby’s group; they concluded that the amide bond cleavage occurs due to 
intramolecular nucleophilic catalysis by the adjacent carboxylic acid group and the rate-
limiting step is the tetrahedral intermediate breakdown [73]. 
 
Figure 2.1. Acid-catalyzed hydrolysis of N-alkylmaleamic acids. 
DFT calculations on the acid-catalyzed hydrolysis of Kirby`s N-alkylmaleamic acids that 
were done by Karaman’s group showed that the rate limiting step in aqueous medium is 
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the collapse of the tetrahedral intermediate  whereas in the gas phase the rate limiting step 
is the formation of the tetrahedral intermediate. Furthermore, Karaman’s calculations 
revealed a correlation between the acid-catalyzed hydrolysis efficiency and the following 
parameters: 
1. The difference between the strain energies of intermediate and product and 
intermediate and reactant.  
2. The distance between the hydroxyl oxygen of the carboxylic group and the amide 
carbonyl carbon. 
3. The attack angle.  
The calculations also demonstrated that the acid catalyzed reaction involves three steps: 
(1) proton transfer from the carboxylic group to the adjacent amide carbonyl oxygen, (2) 
nucleophilic attack of the carboxylate anion onto the protonated carbonyl carbon; and (3) 
dissociation of the tetrahedral intermediate to provide products (Figure 2.2).  
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Figure 2.2. Proposed mechanism for the acid-catalyzed hydrolysis of N-alkylmaleamic 
acids. 
 
Based on the calculation results of Kirby`s model (proton transfer in N-alkylmaleamic 
acids) we propose four tranexamic acid prodrugs, tranexamic acid ProD 1- 4 (Figure 
2.3). 
As shown in Figure 6, tranexamic acid ProD 1- 4 have a carboxylic group (hydrophilic 
moiety) and a lipophilic moiety (the rest of the prodrug), where the combination of both 
moieties secures a relatively moderate HLB. 
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Figure 2.3. Acid-catalyzed hydrolysis of tranexamic acid ProD 1- 4. 
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In most of the  physiologic environments (pH 1- 8.0) tranexamic acid will exist primary 
in the ionized forms (eq.1) while its prodrugs, tranexamic acid ProD 1- 4, will equilibrate 
between the ionic and the free acid forms (eq. 2) especially in a physiological 
environment of  pH 5.5-6.8 (intestine). Thus, it is expected that tranexamic acid ProD 1- 
4 may have a better bioavailability than the parent drug due to neutralizing the ionized 
amine group which results in absorption improvement. In addition, these prodrugs may 
be used in different dosage forms (i.e. enteric coated tablets, topical use and etc.) because 
of their potential solubility in organic and aqueous media due to the ability of the 
carboxylic group to be converted to the corresponding carboxylate anion in a 
physiological pH of around 6.0. 
HOOC
NH2
OH-
H+
-OOC
NH3+
N
H
O
OH
O
COOH
N
H
O
OH
O
COO-
N
H
O
O-
O
COOH NH
O
O-
O
COO-
eqn (1)
eqn (2)
 
It should be emphasized that at pH 5.5-6.5 (SC, skin, mouth cavity and intestine 
physiologic environments), the carboxylic group of the prodrugs will equilibrate with the 
corresponding carboxylate form (eq. 2). Subsequently, the free acid form will undergo 
proton transfer reaction (rate limiting step) to yield the antifibrinolytic drug, tranexamic 
acid, and the inactive linker as a by-product (Figure 6).  
It is worth noting that our proposal is to exploit tranexamic acid prodrugs ProD 1- 4 for 
oral use via enteric coated tablets. At this physiologic environment, these prodrugs will 
exist in the acidic and ionic forms where the equilibrium constant for the exchange 
between the two forms is dependent on the pKa of the given prodrug (eq. 2). The 
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experimental determined pKa1 for tranexamic acid ProD 1- 4 linkers is in the range of 4-
6. Therefore, it is expected that the pKas of the corresponding prodrugs will have similar 
pKa range as for the carboxylic linkers. Since the pH for the small intestine lies in the 
range of 5.5-6.8, the calculated unionized (acidic) /ionized ratio will be in the range of 
10-50%. Although the percentage of the acidic form is not significantly high, we expect 
that these prodrugs to undergo an efficient proton transfer (rate limiting step) to yield the 
antifibrinolytic drug, tranexamic acid. In the blood circulation at pH 7.4, the calculated 
acidic form is around 1% and it is expected that the efficiency for delivering the parent 
drug will be relatively low. Improving the efficiency could be achieved by using 
carboxylic linkers having pKa close to that of the blood circulation (pH 7.4). 
2.3. Designing of paracetamol prodrug based on Bruice’s enzyme model 
Bruice’s group researched the ring-closing reactions of di-carboxylic semi-esters 10-14 
shown in Figure 2.4 and they found that the relative rate (krel) is in the following order 14 
> 13 > 12 > 11 > 10. They attributed the acceleration in rates to proximity orientation. 
Using the observation that alkyl substitution on succinic acid influences rotamer 
distributions, the ratio between the reactive gauche and the unreactive anti-
conformations, they proposed that gem-dialkyl substitution increased the probability of 
the resultant rotamer adopting the more reactive conformation. Hence, for ring-closing to 
occur, the two reacting centers must be in the gauche conformation. In the unsubstituted 
reactant, the reactive centers are almost completely in the anti-conformation in order to 
minimize steric interactions [31, 32] 
Menger and Bruice ascribed the phenomenon of rate enhancement in some 
intramolecular processes to the importance of the orientation (proximity) of the 
nucleophile to the electrophile of the ground state molecules [31, 32, 60, 62, 63]. Menger 
in his “spatiotemporal” hypothesis developed an equation relating activation energy to 
distance and based on this equation, he has reached to the conclusion that significant rate 
accelerations in reactions catalyzed by enzymes are obtained by imposing short distances 
between the reacting centers of the substrate and enzyme [62, 63]. On the other hand, 
Bruice attributed the enzyme catalysis to favorable ‘near attack conformations’. 
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According to Bruice’s hypothesis, systems having a high quota of near attack conformers 
will have a higher intramolecular reaction rate and vice versa. Bruice’s idea invokes a 
combination of distance between the two reacting centers and angle of attack by which 
the nucleophile approaches the electrophile [31, 32]. In contrast to the proximity 
proposal, others believe that high rate acceleration in intramolecular processes is a result 
of steric effects (relief of the reactant’s strain energy) [74].  
 
Figure 2.4. Chemical structures for di-carboxylic semi-esters 10-14. 
Reevaluation of Bruice`s proximity orientation 
For utilizing di-carboxylic semi-esters 10-14 (Figure 2.4) as prodrug moieties for drugs 
containing hydroxyl or phenol group, Karaman’s group have recently unraveled the 
mechanism for their ring-closing reactions using DFT and molecular mechanics (MM2) 
calculation methods (Figure 2.4) [72] . In accordance with the findings by Bruice and 
Pandit [31, 32], Karaman’s study revealed that the ring-closing reaction occurs by one 
mechanism (Figure 2.5), by which the rate-limiting step is the tetrahedral intermediate 
collapse and not its formation. However, contrarily to the conclusion by Bruice, Karaman  
found that the acceleration in rates is due to steric effects rather than to proximity 
orientation stemming from the “rotamer effect” [72]. 
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Figure 2.5. Proposed mechanism for the hydrolysis of di-carboxylic semi-esters. 
 
Based on the calculations study of Bruice’s enzyme model, we propose three paracetamol 
prodrugs, paracetamol prodrugs ProD 1- ProD 3 as shown in (Figure 2.6) have a 
carboxylic acid group as a hydrophilic moiety and the rest of the prodrug as a lipophilic 
moiety, where the combination of both groups provides a moderate HLB. It should be 
noted that the HLB value will be determined upon the physiologic environment by which 
the prodrug is dissolved. For example, in the stomach, paracetamol prodrugs will 
primarily exist in the carboxylic acid form whereas in the blood circulation the 
carboxylate anion form will be predominant. Since Bruice’s cyclization reaction occurs in 
basic medium paracetamol ProD 1-ProD 3 were obtained as carboxylic free acid form, 
since this form is expected to be stable in acidic medium such as the stomach.  
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Figure2.6. Hydrolysis of Paracetamol ProD 1- ProD 3. 
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Chapter Three 
3. Experimental Part 
3.1. Materials 
Inorganic salts were of analytical grade and were used without further purification. 
Distilled water was redistilled twice before use. Maleic anhydride, succinic anhydride, 
2,3-dimethyl maleic anhydride, 2,2-dimethyl succinic anhydride, sodium hydride, 
anhydrous sodium dihydrogen phosphate,  sodium lauryl sulfate,  triethylamine, 
tranexamic acid and paracetamol  were commercially obtained from sigma Aldrich. 
Methanol, acetonitrile and water for analysis were for HPLC grade and were purchased 
from Sigma Aldrich. High purity chloroform, tetrahydrfuran (THF) and diethyl ether (> 
99%) were purchased from Biolab (Israel).  
3.2. Instrumentation 
HPLC measurements were carried out using Shimadzu prominence high performance 
liquid chromatography system HPLC-PDA, (Shimadzu corp. Japan). Samples were 
shaken using Big Bill, (Banstaed/ Themolyne, USA). LC-Esi-MS measurements were 
performed employing an agilent 1200  series liquid chromatography coupled with a 6520 
accurate mass quadruple time of flight mass spectrometer (Q-TOF LC/MS)The high 
pressure liquid chromatography system consisted of a model 2695 HPLC from Waters 
(Israel) equipped with a Waters 2996 Photodiode array. Data acquisition and control were 
carried out using Empower ™ software (Waters: Israel). Analytes were separated on a 4.6 
mm x150 mm C18 XBridge® column (5 µm particle size) used in conjunction with a 4.6 
mm, 20 µm, XBridge® C18 guard column. Microfilters 0.45µm porosity were normally 
used (Acrodisc® GHP, Waters). pH meter model HM-30G: TOA electronics™ was used 
in this study to measure the pH value for the buffers. UV-Spectrophotometer the 
concentrations of samples were determined spectrophotometrically (UV-
spectrophotometer, Model: UV-1601, Shimadzu, Japan) by monitoring the absorbance at 
λmax for each drug. Centrifuge: Labofuge®200 Centrifuge was used, 230 V 50/60 Hz. 
CAT. No.  284811. Made in Germany. 1H-NMR: Data were collected using Varian Unity 
Inova 500 MHz spectrometer equipped with a 5-mm switchable and data were processed 
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using the VNMR software. For 1H-NMR, chemical shifts are reported in parts per million 
(ppm, δ) downfield from tetramethylsilane (TMS). Spin multiplicities are described as s 
(singlet), brs (broad singlet), t (triplet), q (quartet), and m (multiplet). All infrared spectra 
(FTIR) were obtained from a KBr matrix (4000–400 cm-1) using a PerkinElmer
 
Precisely, 
Spectrum 100, FT-IR spectrometer. 
3.3. Synthesis of the Prodrugs 
3.3.1 Tranexamic acid prodrugs (Scheme 1) 
In a 250 ml round-bottom flask tranexamic acid (10 mmol) was dissolved in THF (100 
ml), a solution of 0.5 g NaOH in dry THF was added (50 ml), the resulting solution was 
stirred for 30 minutes, then 10 mmol of maleic anhydride, 2,3-dimethyl maleic anhydride, 
succinic anhydride or 2,2-dimethyl succinic anhydride was slowly added to the reaction 
mixture and stirred at room temperature for 10 hours, then the reaction mixture was 
refluxed for two hours and cooled to room temperature, the white precipitate formed was 
collected and dried. 
Reaction of tranexamic acid with maleic anhydride 2,3-dimethyl maleic anhydride, 
succinic anhydride or 2,2-dimethyl succinic anhydride provided tranexamic acid ProD 1, 
ProD 2, ProD 3 and ProD 4 respectively  with  yields of 87% (2.2g), 92% (2.5 g), 92% 
(2.3 g) and 86% (2.4 g) respectively.  M.P. 201 Co, 240 Co, 220 Co and 215 Co 
respectively. 
Tranexamic acid ProD 1, 1H-NMR δ (ppm) CD3OD- 1.06 (q, 2H, CH-CH2-CH2), 1.40 
(q, 2H, CH-CH2-CH2), 1.54 (m, 1H, CH2-CH-CH2-CH2), 1.84 (m, 2H, CH2-CH2-CH ), 
2.02 (m, 2H, CH2-CH2-CH), 2.22 (m, 1H, CH2-CH-CH2-CH2), 3.17 (d, 2H, J = 6.5 Hz, 
CH2-N), 6.25 (d, 1H, J = 14 Hz, HC=CH), 6.45 (d, 1H, J = 14 Hz, HC=CH). IR (KBr/νmax 
cm–1) 1712 (C=O), 1643 (C=O), 1587 (C=C), 1420, 1280, 1200, 1132, 1058. m/z 
256.1179 (M+1)+. 
Tranexamic acid ProD 2, 1H-NMR δ (ppm) D2O- 1.40 (m, 1H, CH2-CH-CH2), 1.65 (m, 
4H, CH-CH2-CH2-CH-CH2-CH2), 1.73 (m, 2H, CH2-CH2-CH ), 1.93 (s,6H, CH3-C=C-
CH3),  2.02 (m, 2H, CH2-CH2-CH), 2.22 (m, 1H, CH2-CH-CH2-CH2), 3.02 (d, 2H, J = 
7.2 Hz, CH2-N). IR (KBr/νmax cm–1) 1751 (C=O), 1646 (C=O), 1544 (C=C), 1444, 1257, 
1204, 1111, 1012. m/z 566.2905 (2M+1)+. 
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Tranexamic acid  ProD 3, 1H-NMR δ (ppm) CD3OD- 0.97 (m, 1H, CH2-CH-CH2), 1.41 
(m, 4H, CH-CH2-CH2-CH-CH2-CH2), 1.82 (m, 2H, CH2-CH2-CH ), 1.97 (m, 2H, CH2-
CH2-CH), 2.13 (m, 1H, CH2-CH-CH2-CH2), 2.44 (t, J = 4.8 Hz, 2H,CH2-CH2), 2.5 (t, 2H, 
J = 4 Hz, CH2-CH2), 3.02 (d, 2H, J = 6.8 Hz, CH2-N). IR (KBr/νmax cm–1) 1742 (C=O), 
1703 (C=O), 1642 (C=O), 1555, 1383, 1320, 1287, 1240, 1127.  m/z 507.3454 (2M+1)+. 
Tranexamic acid ProD 4. 1H-NMR δ (ppm) CD3OD- 0.97 (m, 1H, CH2-CH-CH2), 1.21(s, 
6H, J = 20 Hz, (CH3)2-C) 1.41 (m, 4H, J = 7 Hz, CH2-CH2-CH-CH2-CH2), 1.82 (m, 2H, 
CH2-CH2-CH), 1.97 (m, 2H, CH2-CH2-CH), 2.13 (m, 1H, CH2-CH-CH2-CH2), 2.51 (s, N-
C=OCH2-C) 3.01 (d, 2H, J = 6.5 Hz, CH2-N). IR (KBr/νmax cm–1) 1750 (C=O) 1645 
(C=O), 1566, 1472, 1372, 1254, 1113, 1015. m/z 286.1627 (M+1)+.  
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3.3.2 Paracetamol prodrugs (Scheme 2) 
In a 250 ml round-bottom flask paracetamol (20 mmol) was dissolved in ether (100 ml), 
1.6g of sodium hydride was added, the resulting solution was stirred for 30 minutes then 
20 mmol) of maleic anhydride, succinic anhydride or glutaric anhydride was slowly 
added to the mixture, then the mixture was stirred overnight. 1N HCl (50 ml) was added 
while the round-bottom flask is setting in an ice bath. The aqueous layer was extracted 
with ether (90 ml) and the combined ether layer was dried over MgSO4 anhydrous, 
filtered and evaporated to dryness. The solid product was washed with hexane and dried 
to yield off-white solid. Reaction of paracetamol with maleic anhydride, succinic 
anhydride or glutaric anhydride provided paracetamol ProD 1, ProD 2, ProD 3 
respectively  with  yield 91% (4.5g) for paracetamol ProD 2 and 88% (4.6 g) for 
paracetamol ProD 3.  M.P. 70 Co and 102 Co for paracetamol ProD 2 and ProD 3, 
respectively. 
Paracetamol ProD 1 was not stable; it was readily hydrolyzed to paracetamol and maleic 
anhydride before the ending of reaction. 
Paracetamol ProD 2. 1H-NMR δ (ppm) CD3OD- 2.05 (s, 3H, CH3-CONH), 2.7 (t, 2H, J = 
4 Hz, CH2-CH2), 2.8 (t, 2H, J = 4 Hz, CH2-CH2), 7.0 (d, 2H, J = 12.4 Hz, aromatic), 7.3 
(d, 2H, J = 8 Hz, aromatic). IR (KBr/νmax cm–1) 1739 (C=O), 1668 (C=O), 1548 (C=C), 
1510, 1280, 1260, 1151. m/z 252.0867 (M+1)+. 
Paracetamol ProD 3. 1H-NMR δ (ppm) CD3OD- 2.0 (m, 2H, CH2-CH2-CH2), 2.1 (s, 3H, 
CH3-CONH), 2.44 (t, J = 4 Hz, 2H, CH2-CH2-COOH), 2.63 (t, J = 4 Hz, 2H, ArOOC-
CH2-CH2), 7.02 (d, 2H, J = 8 Hz, aromatic), 7.5 (d, 2H, J = 8 Hz, aromatic). IR (KBr/νmax 
cm–1) 1748 (C=O), 1704 (C=O), 1556 (C=C), 1441, 1380.  m/z 266.1075 (M+1)+. 
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3.4 Kinetic Methods 
3.4.1 Buffer Preparation 
6.8 g potassium dihydrogen phosphate were dissolve in 900 ml water for HPLC, the pH 
of buffers pH 2 and pH 3 was adjusted by diluted  o- phosphoric acid and water was 
added to a final volume of 1000 ml (0.05M). The same procedure was done for the 
preparation of buffers pH 5 and 7.4, however, the required pH was adjusted using 1 N 
NaOH. 
Intra-conversion of 500 ppm tranexamic acid ProD 1-4 solutions, in 1N HCl, buffer pH 
2, buffer pH 5 or buffer pH 7.4, to its parent drug, tranexamic acid, was followed by 
HPLC at a wavelength of 220 nm. Conversion reactions were run mostly at 37.0 ˚C. 
Intra-conversion of 500 ppm paracetamol ProD 2, ProD 3 solutions, in 1N HCl, buffer 
pH 3 and buffer pH 7.4, to its parent drug, paracetamol, was followed by HPLC at a 
wavelength of 245 nm. Conversion reactions were run mostly at 37.0 ˚C. 
3.4.2 Calibration curve 
A 100 ml stock solution of tranexamic acid ProD 1-4 with a final concentration of 500 
ppm were prepared by dissolving 50 mg from each prodrug in 100 ml methanol. The 
following diluted solutions were prepared from the stock solution: 100, 200, 300 and 400 
ppm. Each solution was then injected to the HPLC apparatus using 6 mm x 250 mm, 5 
µm C18 XBridge ® column, mobile phase contains 11 g anhydrous sodium dihydrogen 
phosphate, 1.4 g Sodium Lauryl Sulfate, 5 ml triethylamine dissolved in 600 ml water 
and 400 ml methanol (pH 2.5 using diluted phosphoric acid), a flow rate of 0.9 ml min-1 
and UV detection at a wavelength of 220 nm. 
Peak area vs. concentration of the pharmaceutical (ppm) was then plotted, and R2 of the 
plot was recorded. 
A 100 ml stock solution of paracetamol ProD 2 and ProD 3 with a final concentration of 
500 ppm were prepared by dissolving 50 mg from each prodrug in 100 ml methanol. The 
following diluted solutions were prepared from the stock solution: 100, 200, 300 and 400 
ppm. Each solution was then injected to the HPLC apparatus using 6 mm x 250 mm, 5 
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µm C18 XBridge ® column, mobile phase water: acetonitrile (80:20), a flow rate of 1 ml 
min-1 and UV detection at a wavelength of 245 nm. 
Peak area vs. concentration of the pharmaceutical (ppm) was then plotted, and R2 of the 
plot was recorded. 
3.5.3 Preparation of standard and sample solution 
3.5.3.1 Tranexamic acid prodrugs 
A 500 ppm of standard tranexamic acid was prepared by dissolving 50 mg of tranexamic 
acid in 100 ml of 1N HCl, buffer pH 2, buffer pH 5 or buffer pH 7.4, then each sample 
was injected into HPLC to detect the retention time of tranexamic acid. 
A 500 ppm of standard linker (maleic anhydride, 2,3-dimethyl maleic anhydride, succinic 
anhydride and 2,2-dimethyl succinic anhydride) was prepared by dissolving 50 mg of 
each linker in 100 ml of 1N HCl, buffer pH 2, buffer pH 5 or buffer pH 7.4, then each 
sample was injected into HPLC to determine the retention time of linker. 
A 500 ppm of each tranexamic acid ProD 1-4 was prepared by dissolving 50 mg of the 
tranexamic acid ProD 1-4  in 100 ml of 1N HCl, buffer pH 2, buffer pH 5 or buffer pH 
7.4 then each sample was injected into the HPLC to determine the retention time. 
The progression of reaction was followed by monitoring the disappearance of the prodrug 
and appearance of tranexamic acid and linker maleic anhydride, 2,3-dimethyl maleic 
anhydride, succinic anhydride, 2,2-dimethyl succinic anhydride with. time. 
3.5.3.2 Paracetamol prodrugs 
A 500 ppm of standard paracetamol was prepared by dissolving 50mg of paracetamol in 
100 ml of 1N HCl, buffer pH 3 and buffer pH 7.4, then each sample was injected into the 
HPLC to determine the retention time of paracetamol. 
A 500 ppm of paracetamol ProD 2 and ProD 3 was prepared by dissolving 50mg of 
paracetamol ProD 2 and ProD 3  in 100 ml of 1N HCl, buffer pH 3 and buffer pH 7.4 
then each sample was injected into the HPLC to determine the retention time of 
paracetamol ProD 2 and ProD 3. 
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The progression of reaction was followed by monitoring the disappearance of prodrug 
and the appearance of parent drug (paracetamol) with time. 
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Chapter Four 
4. Results and Discussion 
Trnexamic acid and paracetamol prodrugs were synthesized, purified and characterized 
using different spectroscopic and chromatographic techniques.   
4.1.  Characterization 
Tranexamic acid, tranexamic acid ProD 1- 4, paracetamol ProD 2 and paracetamol ProD 
3 were characterized by FT-IR, LC-MS and 1H-NMR spectroscopy. 
Tranexamic acid (C8H15NO2). The IR spectrum (Figure 4.1 a) shows an absorbance at 
1642 cm-1 corresponds to C=O, 1425 cm-1, 1280 cm-1, 1256 cm-1, 1132 cm-1, 1058 cm-1. 
A high resolution LC-MS (Figure 4.1 b) at the ESI (positive mode) shows a protonated  
peak at m/z 158.1176 (M+1)+, an adduct of [M+Na]+ was appeared at m/z of 180.0993. 
The 1H-NMR (Figure 4.1 c) peaks occur at  1.06 ppm (q, 2H, CH-CH2-CH2), 1.40 ppm 
(q, 2H, CH-CH2-CH2), 1.54 ppm (m, 1H, CH2-CH-CH2-CH2), 1.84 ppm (m, 2H, CH2-
CH2-CH ), 2.02 ppm (m, 2H, CH2-CH2-CH), 2.22 ppm (m, 1H, CH2-CH-CH2-CH2), 3.17 
ppm (d, 2H, CH2-N). 
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Figure 4.1 a. FT-IR spectrum of tranexamic acid. 
 
 
Figure 4.1 b. LC-MS spectrum of tranexamic acid. 
35 | P a g e  
 
 
Figure 4.1 c. 1H-NMR spectrum of tranexamic acid in CD3OD. 
Tranexamic acid ProD 1 (C12H17NO5). The zoomed IR spectrum (Figure 4.2 a)  shows 
an additional signals with absorbance 1712 cm-1, 1643 cm-1 corresponds to C=O of the 
maleate moiety,. A high resolution LC-MS (Figure 4.2 b) shows a protonated peak at m/z 
256.1179 (M+1) +, an adduct of [M+Na]+ was appeared at m/z of 278.0992. The 1H-NMR 
(Figure 4.2 c) the alkene cis proton show doublet peaks at 6.25. 6.45 with coupling 
constant of 14 Hz, indicate the cis arrangement of these protons.  
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Figure 4.2 a. FT-IR spectrum of tranexamic acid ProD 1. 
 
Figure 4.2 b. LC-MS spectrum of tranexamic acid ProD 1. 
 Figure 4.2 c. 1H-NMR spectrum of tranexamic acid ProD 1
Tranexamic acid ProD 2
an absorbance of the additional carbonyl group (C=O) for the dimethyl maleate moiety 
1751 cm-1, 1646 cm-1 , . A high resolution 
at m/z 566.2905 (2M+1)+. The 
1.93ppm represent the two methyl groups on C=C of the dimethyl maleate moiety.
 in CD3OD.
 (C14H21NO5). The zoomed IR spectrum (Figure 
LC-MS (Figure 4.3 b) shows a 
1H-NMR (Figure 4.3 c) an additional singlet
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Figure 4.3 a. FT-IR spectrum of tranexamic acid ProD 2. 
 
Figure 4.2 b. LC-MS spectrum of tranexamic acid ProD 2. 
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Figure 4.3 c. 1H-NMR spectrum of tranexamic acid ProD 2 in D2O. 
Tranexamic acid ProD 3 (C12H19NO5). The IR spectrum (Figure 4.4 a) shows an 
absorbance at 1742 cm-11 corresponds to the additional carbonyl group (C=O) for the 
succinate moiety,. A high resolution LC-MS (Figure 4.4 b) shows a protonated peak at 
m/z 507.3454 (2M+1)+. The 1H-NMR (Figure 4.4 c) shows an additional a triplet signal 
for the succinate moiety protons occur at 2.44ppm with coupling constant of 4.8 Hz and 
at 2.5 ppm with coupling constant of 4.0 Hz. 
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Figure 4.4 a. FT-IR spectrum of tranexamic acid ProD 3. 
 
Figure 4.4 b. LC-MS spectrum of tranexamic acid ProD 3. 
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Figure 4.4 c. 1H-NMR spectrum of tranexamic acid ProD 3 in CD3OD. 
Tranexamic acid ProD 4 (C14H23NO5). The zoomed IR spectrum (Figure 4.5 a) shows 
an absorbance at 1750 cm-1corresponds to the carbonyl groub (C=O) of dimetyl succinate 
moiety. A high resolution  LC-MS (Figure 4.5 b) shows a protonated peak at m/z 
286.1627 (M+1)+. 1H-NMR (Figure 4.5 c) the protons for the two methyl groups of the 
dimethyl succinate moiety show a singlet peak at 1.21 ppm with coupling constant of 20 
Hz.  
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Figure 4.5 a. FT-IR spectrum of tranexamic acid ProD 4. 
 
Figure 4.5 b. LC- MS spectrum of tranexamic acid ProD 4. 
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Figure 4.5 c. 1H-NMR spectrum of tranexamic acid ProD 4 in CD3OD. 
Paracetamol (C8H9NO2). The IR spectrum (Figure 4.6 a) shows an absorbance at 
1612cm-1 corresponds to C=C and 1567 cm-1 corresponds to C=C. The 1H-NMR (Figure 
4.6 b) peaks occur at 2.1 ppm (s, 3H, CH3-CONH), 6.7 ppm (d, 2H, J = 12.4 Hz, 
aromatic), 7.3 ppm (d, 2H, J = 8Hz, aromatic). 
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Figure 4.6 a. FT-IR spectrum of paracetamol. 
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Figure 4.6 b. 1H-NMR spectrum of paracetamol in CD3OD. 
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Paracetamol ProD 2 (C12H13NO5). The zoomed IR spectrum (Figure 4.7 a) shows an 
additional signal with absorbance of 1750 cm-1corresponds to carbonyl group (C=O) for 
the succinate moiety. A high resolution LC-MS (Figure 4.7 b) shows a protonated peak at 
m/z 252.0867 (M+1)+. The 1H-NMR (Figure 4.7 c) shows two additional triblet  peaks 
occur at 2.7 ppm and 2.8 ppm with coupling constant of 4 Hz corresponding to the four 
protons of the succinate moiety.   
 
Figure 4.7 a. FT-IR spectrum of paracetamol ProD 2. 
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Figure 4.7 b. LC- MS spectrum of paracetamol ProD 2. 
 
Figure 4.7 c. 1H-NMR spectrum of paracetamol ProD 2 in CD3OD. 
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Paracetamol ProD 3 (C13H15NO5). The zoomed IR spectrum (Figure 4.8 a) shows an 
absorbance at 1748 cm-1,corresponds to the additional carbonyl group (C=O) for the 
glutarate moiety.  A high resolution LC-MS (Figure 4.8 b) shows a protonated peak at 
m/z 266.1075 (M+1)+. 1H-NMR (Figure 4.8 c) the six protons for the glutarate moity 
occur at 2.0 ppm with multiplet signal and a triplet signal at 2.44 ppm, 2.63 ppm with 
coupling constant of 4Hz.  
 
Figure 4.8 a. FT-IR spectrum of paracetamol ProD 3. 
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Figure 4.8 b. LC- MS spectrum of paracetamol ProD 3. 
 
Figure 4.8 c. 1H-NMR spectrum of paracetamol ProD 3 in CD3OD. 
The IR, 1H-NMR and LC-MS spectral results mentioned before, confirmed that the 
desired prodrugs are obtained from each reaction. 
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4.2 Calibration curve for tranexamic acid ProD 1- 4, paracetaml ProD 2, ProD 3 
In order to follow the fact of the prodrugs kinetic calibration curves were obtained by 
plotting the HPLC peak area versus concentration as displayed in Figure 4.9 for 
tranexamic acid ProD 1- 4 and Figure 4.10 for paracetamol ProD 2, ProD 3. As shown 
in the figures, excellent linearity with correlation coefficient (R2) of 0.995, 0.970, 0.995 
and 0.982 for tranexamic acid ProD 1-4 respectively, and the (R2) was 0.995 for 
paracetamol ProD 2 and ProD 3 was obtained. 
 
Figure 4.9. Calibration curves for tranexamic acid ProD 1-4. 
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Figure 4.10. Calibration curves for paracetamol ProD 2 and ProD 3.  
4.3.Hydrolysis studies 
4.3.1. Tranexamic acid ProD 1-4: 
The kinetics of the acid-catalyzed hydrolysis studies were carried out in aqueous buffer in 
the same manner as that done by Kirby on Kirby’s enzyme model 1-9 [73]. This is in 
order to explore whether the prodrug hydrolyzes in aqueous medium and to what extent, 
suggesting the fate of the prodrug in the system. Acid-catalyzed hydrolysis kinetics of the 
synthesized tranexamic acid ProD 1-4 were studied in four different aqueous media, 1N 
HCl, buffer pH 2, buffer pH 5 and buffer pH 7.4. Under the experimental conditions, the 
target compounds hydrolyzed to release the parent drug as evident by HPLC analysis. At 
constant pH and temperature, the reaction displayed strict first order kinetics as the kobs 
was fairly constant and a straight plot was obtained on plotting log concentration of 
residual prodrug vs. time. The rate constant (kobs) and the corresponding half-lives (t1/2) 
for tranexamic acid prodrug ProD 1-4 in the different media were calculated from the 
linear regression equation correlating the log concentration of the residual prodrug vs. 
time. The 1N HCl and pH 2 were selected to examine the intra-conversion of the 
tranexamic acid prodrug in pH as of stomach, because the mean fasting stomach pH of 
adult is approximately 1-2. In addition, buffer pH 5 mimics the beginning small intestine 
pathway. pH 7.4 was selected to examine the intra-conversion of the tested prodrug in 
blood circulation system. Acid-catalyzed hydrolysis of the tranexamic acid ProD 1 was 
found to be higher at 1N HCl than at pH 2 and 5 (Figures 4.11, 4.12, 4.13 and 4.14). At 
1N HCl, the prodrug was hydrolyzed to release the parent drug in less than one hour. On 
the other hand, at pH 7.4, the prodrug was entirely stable and no release of the parent 
52 | P a g e  
 
drug was observed. Since the pKa of tranexamic acid ProD 1 is in the range of 3-4, it is 
expected that at pH 5 the anionic form of the prodrug will be dominant and the 
percentage of the free acid form that undergoes the acid-catalyzed hydrolysis will be 
relatively low. At 1N HCl and pH 2, most of the prodrug will exist as the free acid form 
and at pH 7.4 most of the prodrug will be in the anionic form. Thus the discrepancy in 
rates at the different pH buffers. The kinetic data are listed in Table 4.1. Acid catalyzed 
hydrolysis of tranexamic acid ProD 2 was found to be readily intraconverted at 1N HCl 
and pH 2, while it was stable at pH 5 and 7.4; according to structural feature of 2,3-
dimethyl maleic moiety it contains two methyl groups on the C-C double bond (strained 
system) which results in a decrease of the distance between the two reactive centers 
(hydroxyl oxygen of the carboxylic group and the amide carbonyl carbon). Hence, the 
hydrolysis in 1N HCl and pH 2 of tranexamic acid ProD 2 is faster than that of 
tranexamic acid ProD 1, Table 4.2 summarize the kinetic data for tranexamic acid ProD 
2. 
In the case of tranexamic acid ProD 3 and ProD 4 the interatomic distance between the 
neucleophile (OH) and electrophile (C=O) is too high to make the nucleophile attack 
accessible. Hence, no reaction was observed with these two prodrugs (Table 4.3 and 4.4). 
 
Table 4.1: The observed k value and t1/2 for the intraconverion of tranexamic acid ProD 
1 in 1N HCl and at pH 2, pH 5 and pH 7.4. 
Medium kobs (h-1) t½ (h) 
1N HCl 5.13 x 10-3 0.9 
Buffer pH 2 3.92 x 10-5 23.9 
Buffer pH 5 3.92 x 10-6 270 
Buffer pH 7.4 No reaction No reaction 
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Table 4.2: The observed k value and t1/2 for the intraconverion of tranexamic acid ProD 
2 in 1N HCl and at pH 2, pH 5 and pH 7.4. 
Medium kobs (h-1) t½ (h) 
1N HCl Readily released Readily released 
Buffer pH 2 Readily released Readily released 
Buffer pH 5 No reaction No reaction 
Buffer pH 7.4 No reaction No reaction 
 
Table 4.3: The observed k value and t1/2 for the intraconverion of tranexamic acid ProD 
3 in 1N HCl and at pH 2, pH 5 and pH 7.4. 
Medium kobs (h-1) t½ (h) 
1N HCl No reaction No reaction 
Buffer pH 2 No reaction No reaction 
Buffer pH 5 No reaction No reaction 
Buffer pH 7.4 No reaction No reaction 
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Table 4.4: The observed k value and t1/2 for the intraconverion of tranexamic acid ProD 
4 in 1N HCl and at pH 2, pH 5 and pH 7.4. 
Medium kobs (h-1) t½ (h) 
1N HCl No reaction No reaction 
Buffer pH 2 No reaction No reaction 
Buffer pH 5 No reaction No reaction 
Buffer pH 7.4 No reaction No reaction 
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Figure 4.11. Chromatograms showing the intra-conversion of tranexamic acid ProD 1 in 1N 
HCl (a) at zero time, (b) at the end of reaction. 
Figure 4.12. Chromatograms showing the intra-conversion of tranexamic acid ProD 1 at pH 2 
(a) at zero time, (b) after 24 hours, (c) at the end of reaction. 
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Figure 4.13. Chromatograms showing the intra-conversion of tranexamic acid ProD 1 at 
pH 5 (a) at zero time, (b) after 250 hours. 
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Figure 4.14. First order hydrolysis plot for the intraconverion of tranexamic acid ProD 1 
in (a) 1N HCl, (b) buffer pH 2 and (c) buffer pH 5. 
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4.3.2. Paracetmol ProD 2 and ProD 3 
The hydrolysis reactions of paracetamol ProD 2 and ProD 3 were studied in three 
different media; 1N HCl, buffer pH 3 and buffer pH 7.4. The prodrug hydrolysis was 
monitored using HPLC analysis (Figures 4.15 and 4.16). At constant pH and temperature 
the release of paracetamol from its prodrugs was followed and showed a first order 
kinetics.  kobs (h-1) and t1/2 values for the intra-conversion of paracetamol ProD 2 and 
ProD 3  were calculated from regression equation obtained from plotting log 
concentration of residual of paracetamol ProD 2 or ProD 3  vs. time (Figures 4.17 and 
4.18). The kinetics results for paracetamol ProD 2 and paracetamol ProD 3 in the 
different media are summarized in Tables 4.5 and 4.6. 
As shown in Tables 5 and 6 the hydrolysis rate of paracetamol ProD 2 and paracetamol 
ProD 3 at pH 7.4 was the fastest among all media, followed by the medium of pH 3. In 
1N HCl no conversion of the prodrug to the parent dug was observed. 
 
Table 4.5: The observed k value and t1/2 for the intra-conversion of paracetamol ProD 2 
in 1N HCl and buffers pH 3 and 7.4. 
Medium kobs (h-1) t½ (h) 
1N HCl No reaction No reaction 
Buffer pH 3 6.3 x 10-5 3 
Buffer pH 7.4 6.1 x 10-4 0.3 
 
Table 4.6: The observed k value and t1/2 for the intra-conversion of  paracetamol ProD 3 
in 1N HCl and buffers pH 3 and 7.4. 
Medium kobs (h-1) t½ (h) 
1N HCl No reaction No reaction 
Buffer pH 3 7.5 x 10-6 27 
Buffer pH 7.4 9.02 x 10-5 12 
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Figure 4.15. Chromatograms showing the intra-conversion of paracetamol ProD 3 at pH 
3 (a) at zero time, (b) after 4 hours, (c) at the end of reaction. 
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Figure 4.16.  Chromatograms showing the intra-conversion of paracetamol ProD 3 at pH 
7.4 (a) at zero time, (b) after 4 hours, (c) at the end of reaction. 
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Figure 4.17. First order hydrolysis plot for paracetamol ProD 2 in (a) buffer pH 3 and (b) 
buffer pH 7.4. 
 
Figure 4.18. First order hydrolysis plot for paracetamol ProD 3 in (a) buffer pH 3 and (b) 
buffer pH 7.4. 
At pH 7.4 paracetamol ProD 2 and ProD 3 are mainly exist as carboxylate anion forms 
that are expected to undergo fast hydrolysis according to Bruice’s mechanism shown in 
Figure 2.5 [72]. At pH 3, the prodrugs exist in both forms, the anion and the free 
carboxylic acid forms due to the fact that the pKa of the prodrugs is around 3. In 1N HCl, 
the prodrugs are entirely exist as the carboxylic free acid form and since only the 
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carboxylate anion form undergoes Bruice’s cyclization the hydrolysis rate in 1N HCl is 
almost negligible or zero. 
In vitro binding for paracetamol ProD 2 to bitter taste receptors was tested in Germany 
and the result revealed that this prodrug lacks any binding affinity and it was found not to 
have any bitter sensation. 
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Chapter Five 
5. Conclusions and Future directions 
5.1. Conclusions: 
Based on Kirby`s enzyme model (Proton transfer in N-alkylmaleamic acids) four 
different tranexamic acid prodrugs were synthesized and their acid-catalyzed hydrolysis 
demonstrated that the rate-limiting step was the collapse of the tetrahedral intermediate. 
The experimental t 1/2 value for tranexamic acid ProD 1 in 1N HCl, buffer pH 2 and 
buffer pH 5 were 54 minutes, 23.9 hours and 270 hours, respectively. On the other hand, 
no hydrolysis was observed at pH 7.4. The lack of the hydrolysis at pH 7.4 might be due 
to the fact that at this pH tranexamic acid ProD 1 exists mainly in the ionized form (pKa 
about 4) taking into consideration that the free acid form is a mandatory requirement for 
the acid-catalyzed hydrolysis to proceed. Tranexamic acid ProD 2 was readily converted 
in 1 N HCl and pH 2 while it was stable at pH 5 and pH 7.4. Tranexamic acid ProD 3 
and Prod 4 were stable in 1 N HCl, pH 2, pH 5 and pH 7.4 and no reaction was observed. 
This may be due to the long interatomic distance between the nucleophile (OH) and 
electrophile (C=O) which renders any nucleophile attack. Hence additional tranexamic 
acid prodrugs with reasonable intra-conversion rate at pH 6.5 and pH 7.4 can be 
synthesized  
Bruice’s enzyme model was used to design, synthesize three different bitterless 
paracetamol prodrugs. In vitro kinetic study of paracetamol ProD 2 and ProD 3 was 
performed in 1 N HCl, pH 3 and pH 7.4. Both prodrugs were stable in 1N HCl, whereas, 
they intraconverted to release their parent drug (paracetamol) in pH 3 and pH 7.4. The 
experimental t 1/2 values for Paracetamol ProD 2 in pH 3 and pH 7.4 were 3 hours and 18 
minutes respectively, while that for paracetamol ProD 3 in pH 3 and pH 7.4 were 27 
hours and 12 hours, respectively. In vitro biding for paracetamol ProD 2 to bitter taste 
receptors revealed that this prodrug lacks any binding affinity and it was found not to 
have any bitter sensation. This suggests, that paracetamol ProD 2 can replace its parent 
drug, paracetamol, for the use as bitterless antipyretic drug for geriatrics and pediatrics 
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5.2. Future directions: 
Synthesis of additional tranexamic acid prodrugs that may be intra-converted to their 
parent drug, tranexamic acid, at pH 6.5 (intestine) and pH 7.4 (blood circulation system). 
In vivo pharmacokinetic studies will be done in order to determine the bioavailability and 
the duration of action of the tested prodrugs.  
In vivo pharmacokinetic studies for paracetamol ProD 2 and in vitro binding for 
paracetamol ProD 3 to bitter taste receptors will be done. 
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